GOVERNMENT OF INDIA/भारत सरकार

MINISTRY OF RAILWAYS/रेल मंत्रालय

(RAILWAY BOARD/रेलवे बोर्ड**)**

No. 2025/H/4/1/DP/Johnson&Johnson **New Delhi dated: 08.10.2025.**

Principal Chief Medical Director
Central Railway
Mumbai.

Sub:-Renewal of registration of drug/pharmaceutical products supply firm M/s. Johnson & Johnson Private Limited-reg.

Ref:- E-3500103 & CR-HQ0MISC/38/2025-O/o PCMD/HQ/CR.

*****

Kind attention is invited to Zone's file cited under reference on the subject cited above. As approved by the competent authority, the firm **M/s. Johnson & Johnson Private Limited** is renewed with the validity upto **07/10/2028.**

Digitally signed by
NITI KUMARI
Date: 08-10-2025
16:34:49

Dr. Niti Kumari/(डॉ**.** नीती कुमारी**)**

Joint Director/IH (संयुक्त निदेशक**/**औद्योगिक स्वास्थ्य**)**

Railway Board/ रेलवे बोर्ड

Tele No. 011-47843133

4th Floor, Room No. 404.

E-mail:- jdihealth@rb.railnet.gov.in

Copy to:- PCMD(s)/PCMO(s), all Indian Railways including PUs & RDSO.

COFMOW Railway Offices Complex, Tilak Bridge, New Delhi-110002.

Johnson & Johnson Private Limited
Corporate Office: Arena Space, Off JVLR, Behind Majas Depot, Jogeshwari E, Mumbai 400 060, India
Registered Office: Higi House, L.B.S. Marg, Mulund (W), Mumbai 400 080
CIN: U33110MH1957PTC010928

TELEPHONE: +91 22 6664 6464
TELEPHONE: +91 22 2593 6700
Web: www.jnjindia.com
Email ID: ra-corporatesecretar@its.jnj.com

LIST OF PRODUCTS

Name of the firm: M/s Johnson & Johnson Pvt. Ltd.

Address: Registered Office: Higi House L.B.S. Marg, Mulund (W), Mumbai 400080

Corporate Office: 501, Arena Space, Behind Majas Bus Depot, Off. J.V. Link Road, Jogeshwari (East), Mumbai- 400060

Turnover of the firm for last three years: Rs. 698.75Cr (2021-22), Rs. 756.48 Cr (2022-23), Rs. 863.44 Cr (2023-24)

Number of the Products for which the firm is qualifying as per the declaration given by the firm:

Sl.No	Brand Name	Pharmacological Name of Medicine	Strength	Manufacturing Unit	Manufacturing Unit Inspected or not
1	Darzalex® 100 mg	Daratumumab concentrate for solution for infusion 100mg	100mg	M/s. Cilag AG, , Hochstrasse 201, Schaffhausen (Switzerland) - CH-8200	Import Drug
2	Darzalex® 400 mg	Daratumumab concentrate for solution for infusion 400mg	400mg	M/s. Cilag AG, , Hochstrasse 201, Schaffhausen (Switzerland) - CH-8200	Import Drug
3	DARZALEX FASPRO	Daratumumab concentrate for solution for infusion 1800mg	1800mg	M/s. Cilag AG, , Hochstrasse 201, Schaffhausen (Switzerland) - CH-8200	Import Drug
4	Imbruvica®	Ibrutinib capsules 140 mg	140mg	M/s. Cilag AG, , Hochstrasse 201, Schaffhausen (Switzerland) - CH-8200	Import Drug
5	Invega Sustenna® 100 mg	Paliperidone Palmitate Prolonged Release Suspension for Injection	100mg	M/s. Janssen Pharmaceutica NV, , Turnhoutseweg 30, B-2340, Beerse Beerse(Belgium) - 2340	Import Drug
6	Invega Sustenna® 150 mg	Paliperidone Palmitate Prolonged Release Suspension for Injection	150mg	M/s. Janssen Pharmaceutica NV, , Turnhoutseweg 30, B-2340, Beerse Beerse(Belgium) - 2340	Import Drug

For JOHNSON & JOHNSON PVT. LTD

Revati Asawale

Digitally signed by Revati Asawale
DN: c=US, o=JNJ, ou=Subscribers, cn=Revati Asawale, 0.9.2342.19200300.100.1.1=152930953
Reason: I am the author of this document
Date: 2025.06.05 17:40:05 +05'30'

Revati Asawale
Lead -Tender Strategy & Operations
Address: 501, Arena Space, Behind Majas Bus Depot, Off. J.V. Link Road, Jogeshwari (East), Mumbai- 400060
M: +91 99202 77765
Email: RAsawale@ITS.JNJ.com

SHOBHA JAGANNATH

Digitally signed by SHOBHA JAGANNATH
Date: 2025.06.11 23:52:41 +05'30'

All contents © Johnson & Johnson Private Limited 2024.

Johnson & Johnson Private Limited
Corporate Office: Arena Space, Off JVLR, Behind Majas Depot, Jogeshwari E, Mumbai 400 060, India
Registered Office: Higi House, L.B.S. Marg, Mulund (W), Mumbai 400 080
CIN: U33110MH1957PTC010928

TELEPHONE: +91 22 6664 6464
TELEPHONE: +91 22 2593 6700
Web: www.jnjindia.com
Email ID: ra-corporatesecretar@its.jnj.com

Sl.No	Brand Name	Pharmacological Name of Medicine	Strength	Manufacturing Unit	Manufacturing Unit Inspected or not
7	Invega Sustenna® 75 mg	Paliperidone Palmitate Prolonged Release Suspension for Injection	75mg	M/s. Janssen Pharmaceutica NV, , Turnhoutseweg 30, B-2340, Beerse Beerse(Belgium) - 2340	Import Drug
8	Remicade®	Each Vial (on reconstitution) contains:- Infliximab 100mg in 10ml	100mg	M/s. Cilag AG, , Hochstrasse 201, Schaffhausen (Switzerland) - CH-8200	Import Drug
9	Risperdal Consta® 25 mg	Risperidone long-acting injection	25mg	M/s. Cilag AG, , Hochstrasse 201, Schaffhausen (Switzerland) - CH-8200	Import Drug
10	Risperdal Consta® 37.5 mg	Risperidone long-acting injection	37.5mg	M/s. Cilag AG, , Hochstrasse 201, Schaffhausen (Switzerland) - CH-8200	Import Drug
11	Risperdal Consta® 50 mg	Risperidone long-acting injection	50mg	M/s. Cilag AG, , Hochstrasse 201, Schaffhausen (Switzerland) - CH-8200	Import Drug
12	Simponi® 50 mg	Golimumab Solution for Injection 50 mg	50mg	M/s. Cilag AG, , Hochstrasse 201, Schaffhausen (Switzerland) - CH-8200	Import Drug

For JOHNSON & JOHNSON PVT. LTD

Revati Asawale

Digitally signed by Revati Asawale
DN: c=US, o=JNJ, ou=Subscribers, cn=Revati Asawale, 0.9.2342.19200300.100.1.1=152930953
Reason: I am the author of this document
Date: 2025.06.05 17:40:35 +05'30'

SHOBHA JAGANNATH

Digitally signed by SHOBHA JAGANNATH
Date: 2025.06.11 23:54:18 +05'30'

Revati Asawale
Lead -Tender Strategy & Operations
Address: 501, Arena Space, Behind Majas Bus Depot, Off. J.V. Link Road, Jogeshwari (East), Mumbai- 400060
M: +91 99202 77765
Email: RAsawale@ITS.JNJ.com

All contents © Johnson & Johnson Private Limited 2024.

Johnson & Johnson Private Limited
Corporate Office: Arena Space, Off JVLR, Behind Majas Depot, Jogeshwari E, Mumbai 400 060, India
Registered Office: Higi House, L.B.S. Marg, Mulund (W), Mumbai 400 080
CIN: U33110MH1957PTC010928

TELEPHONE: +91 22 6664 6464
TELEPHONE: +91 22 2593 6700
Web: www.jnjindia.com
Email ID: ra-corporatesecretar@its.jnj.com

Sl.No	Brand Name	Pharmacological Name of Medicine	Strength	Manufacturing Unit	Manufacturing Unit Inspected or not
13	Rybrevant® 350 mg	Amivantamab Liquid Concentrate for infusion 350 mg	350mg/7ml	M/s. Cilag AG, , Hochstrasse 201, Schaffhausen (Switzerland) - CH-8200	Import Drug
14	Stelara® 90 mg	Ustekinumab Solution for Injection 90 mg	90mg/1ml	M/s. Cilag AG, , Hochstrasse 201, Schaffhausen (Switzerland) - CH-8200	Import Drug
15	Stelara® 130 mg	Ustekinumab Concentrate Solution for Intravenous Infusion 130 mg	130mg/26ml	M/s. Cilag AG, , Hochstrasse 201, Schaffhausen (Switzerland) - CH-8200	Import Drug
16	Tecvayli 30 mg	Teclistamab Solution for Injection 30 mg	30mg	M/s. Janssen Biologicals B.V.Einsteninweg 101, 2333 CB Leiden, The Nethlands Leiden Netherlands	Import Drug
17	Tecvayli 153 mg	Teclistamab Solution for Injection 153 mg	153mg	M/s. Janssen Biologicals B.V.Einsteninweg 101, 2333 CB Leiden, The Nethlands Leiden Netherlands	Import Drug
18	Tremfya	Guselkumab Solution for Injection 100 mg	100mg	M/s. Cilag AG, , Hochstrasse 201, Schaffhausen (Switzerland) - CH-8200	Import Drug

For JOHNSON & JOHNSON PVT. LTD

Revati Asawale

Digitally signed by Revati Asawale
DN: c=US, o=JNJ, ou=Subscribers, cn=Revati Asawale, 0.9.2342.19200300.100.1.1=152930953
Reason: I am the author of this document
Date: 2025.06.05 17:41:07 +05'30'

SHOBHA JAGANNATH

Digitally signed by SHOBHA JAGANNATH
Date: 2025.06.11 23:55:19 +05'30'

Revati Asawale
Lead -Tender Strategy & Operations
Address: 501, Arena Space, Behind Majas Bus Depot, Off. J.V. Link Road, Jogeshwari (East), Mumbai- 400060
M: +91 99202 77765
Email: RAsawale@ITS.JNJ.com

All contents © Johnson & Johnson Private Limited 2024.